255 related articles for article (PubMed ID: 24735367)
1. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.
Kolosenko I; Grander D; Tamm KP
Curr Med Chem; 2014; 21(26):3042-7. PubMed ID: 24735367
[TBL] [Abstract][Full Text] [Related]
2. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
4. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibitors as therapy for multiple myeloma.
Usmani SZ; Chiosis G
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S77-81. PubMed ID: 22035754
[TBL] [Abstract][Full Text] [Related]
6. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.
Chatterjee M; Jain S; Stühmer T; Andrulis M; Ungethüm U; Kuban RJ; Lorentz H; Bommert K; Topp M; Krämer D; Müller-Hermelink HK; Einsele H; Greiner A; Bargou RC
Blood; 2007 Jan; 109(2):720-8. PubMed ID: 17003370
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.
Chatterjee M; Andrulis M; Stühmer T; Müller E; Hofmann C; Steinbrunn T; Heimberger T; Schraud H; Kressmann S; Einsele H; Bargou RC
Haematologica; 2013 Jul; 98(7):1132-41. PubMed ID: 23065523
[TBL] [Abstract][Full Text] [Related]
8. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
9. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway.
Sagawa M; Nakazato T; Uchida H; Ikeda Y; Kizaki M
Cancer Sci; 2008 Sep; 99(9):1820-6. PubMed ID: 18544087
[TBL] [Abstract][Full Text] [Related]
10. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
13. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.
Kudo C; Yamakoshi H; Sato A; Ohori H; Ishioka C; Iwabuchi Y; Shibata H
Anticancer Res; 2011 Nov; 31(11):3719-26. PubMed ID: 22110192
[TBL] [Abstract][Full Text] [Related]
14. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
15. A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.
Amet R; Previtali V; Mihigo HB; Sheridan E; Brophy S; Hante NK; Santos-Martinez MJ; Hayden PJ; Browne PV; Rozas I; McElligott AM; Zisterer DM
Life Sci; 2022 Feb; 290():120236. PubMed ID: 34953891
[TBL] [Abstract][Full Text] [Related]
16. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
17. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3.
Sato N; Yamamoto T; Sekine Y; Yumioka T; Junicho A; Fuse H; Matsuda T
Biochem Biophys Res Commun; 2003 Jan; 300(4):847-52. PubMed ID: 12559950
[TBL] [Abstract][Full Text] [Related]
18. Untangling the unfolded protein response.
Davenport EL; Morgan GJ; Davies FE
Cell Cycle; 2008 Apr; 7(7):865-9. PubMed ID: 18414035
[TBL] [Abstract][Full Text] [Related]
19. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
20. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]